Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242).

Shaffer CL, Patel NC, Schwarz J, Scialis RJ, Wei Y, Hou XJ, Xie L, Karki K, Bryce DK, Osgood SM, Hoffmann WE, Lazzaro JT, Chang C, McGinnis DF, Lotarski SM, Liu J, Obach RS, Weber ML, Chen L, Zasadny KR, Seymour PA, Schmidt CJ, Hajós M, Hurst RS, Pandit J, O'Donnell CJ.

J Med Chem. 2015 May 28;58(10):4291-308. doi: 10.1021/acs.jmedchem.5b00300. Epub 2015 May 14.

PMID:
25905800
2.

Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators.

Patel NC, Schwarz J, Hou XJ, Hoover DJ, Xie L, Fliri AJ, Gallaschun RJ, Lazzaro JT, Bryce DK, Hoffmann WE, Hanks AN, McGinnis D, Marr ES, Gazard JL, Hajós M, Scialis RJ, Hurst RS, Shaffer CL, Pandit J, O'Donnell CJ.

J Med Chem. 2013 Nov 27;56(22):9180-91. doi: 10.1021/jm401274b. Epub 2013 Nov 11.

PMID:
24215237
3.

Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574.

Shaffer CL, Hurst RS, Scialis RJ, Osgood SM, Bryce DK, Hoffmann WE, Lazzaro JT, Hanks AN, Lotarski S, Weber ML, Liu J, Menniti FS, Schmidt CJ, Hajós M.

J Pharmacol Exp Ther. 2013 Oct;347(1):212-24. doi: 10.1124/jpet.113.204735. Epub 2013 Jul 30.

PMID:
23899905
4.

Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism.

Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, Bryce DK, Smith DL, Fonseca K, Ring RH, Crawley JN.

Sci Transl Med. 2012 Apr 25;4(131):131ra51. doi: 10.1126/scitranslmed.3003501.

5.

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models.

O'Donnell CJ, Rogers BN, Bronk BS, Bryce DK, Coe JW, Cook KK, Duplantier AJ, Evrard E, Hajós M, Hoffmann WE, Hurst RS, Maklad N, Mather RJ, McLean S, Nedza FM, O'Neill BT, Peng L, Qian W, Rottas MM, Sands SB, Schmidt AW, Shrikhande AV, Spracklin DK, Wong DF, Zhang A, Zhang L.

J Med Chem. 2010 Feb 11;53(3):1222-37. doi: 10.1021/jm9015075.

PMID:
20043678
6.

Biaryl piperidines as potent and selective delta opioid receptor ligands.

Liras S, McHardy SF, Allen MP, Segelstein BE, Heck SD, Bryce DK, Schmidt AW, Vanase-Frawley M, Callegari E, McLean S.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):503-7. doi: 10.1016/j.bmcl.2009.11.113. Epub 2009 Nov 26.

PMID:
20015649
7.

Design, synthesis and biological evaluation of 3-amino-3-phenylpropionamide derivatives as novel mu opioid receptor ligands.

Allen MP, Blake JF, Bryce DK, Haggan ME, Liras S, McLean S, Segelstein BE.

Bioorg Med Chem Lett. 2000 Mar 20;10(6):523-6.

PMID:
10741545
8.

Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist.

Rosen TJ, Coffman KJ, McLean S, Crawford RT, Bryce DK, Gohda Y, Tsuchiya M, Nagahisa A, Nakane M, Lowe JA 3rd.

Bioorg Med Chem Lett. 1998 Feb 3;8(3):281-4.

PMID:
9871670
9.

Design of novel cholecystokinin-B receptor ligands based on the 'double-ring system' approach.

Lowe JA 3rd, Qian W, McLean S, Bryce DK, Crawford RT, Olsson LC, Bordner J.

Regul Pept. 1996 Aug 27;65(1):11-4.

PMID:
8876030
10.

Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.

McLean S, Ganong A, Seymour PA, Bryce DK, Crawford RT, Morrone J, Reynolds LS, Schmidt AW, Zorn S, Watson J, Fossa A, DePasquale M, Rosen T, Nagahisa A, Tsuchiya M, Heym J.

J Pharmacol Exp Ther. 1996 May;277(2):900-8.

PMID:
8627572
11.

5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.

Lowe JA 3rd, Hageman DL, Drozda SE, McLean S, Bryce DK, Crawford RT, Zorn S, Morrone J, Bordner J.

J Med Chem. 1994 Oct 28;37(22):3789-811.

PMID:
7966138
12.

Aza-tricyclic substance P antagonists.

Lowe JA 3rd, Drozda SE, McLean S, Bryce DK, Crawford RT, Snider RM, Longo KP, Nagahisa A, Tsuchiya M.

J Med Chem. 1994 Sep 2;37(18):2831-40.

PMID:
7520943
13.

Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor.

McLean S, Ganong A, Seymour PA, Snider RM, Desai MC, Rosen T, Bryce DK, Longo KP, Reynolds LS, Robinson G, et al.

J Pharmacol Exp Ther. 1993 Oct;267(1):472-9.

PMID:
7693914
14.

CP-99,994, a nonpeptide antagonist of the tachykinin NK1 receptor.

McLean S, Snider RM, Desai MC, Rosen T, Bryce DK, Longo KP, Schmidt AW, Heym J.

Regul Pept. 1993 Jul 2;46(1-2):329-31. No abstract available.

PMID:
8210497
15.

Discovery of CP-96,345 and its characterization in disease models involving substance P.

Lowe JA 3rd, Drozda SE, Snider RM, Longo KP, Zorn SH, Jackson ER, Morrone J, McLean S, Bryce DK, Bordner J, et al.

Regul Pept. 1993 Jul 2;46(1-2):20-3. Review.

PMID:
7692490
16.

The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst.

Lowe JA 3rd, Drozda SE, Snider RM, Longo KP, Zorn SH, Morrone J, Jackson ER, McLean S, Bryce DK, Bordner J, et al.

J Med Chem. 1992 Jul 10;35(14):2591-600. Erratum in: J Med Chem 1992 Dec 11;35(25):4768.

PMID:
1378901
17.

Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist.

McLean S, Ganong AH, Seeger TF, Bryce DK, Pratt KG, Reynolds LS, Siok CJ, Lowe JA 3rd, Heym J.

Science. 1991 Jan 25;251(4992):437-9.

PMID:
1703324

Supplemental Content

Loading ...
Support Center